194 related articles for article (PubMed ID: 32346617)
1. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines.
Abdul Rahman SF; Muniandy K; Soo YK; Tiew EYH; Tan KX; Bates TE; Mohana-Kumaran N
Biochem Biophys Rep; 2020 Jul; 22():100756. PubMed ID: 32346617
[TBL] [Abstract][Full Text] [Related]
2. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
3. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X
Kehr S; Haydn T; Bierbrauer A; Irmer B; Vogler M; Fulda S
Cancer Lett; 2020 Jul; 482():19-32. PubMed ID: 32145345
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of Nasopharyngeal carcinoma cells.
Abdul Rahman SF; Azlan A; Lo KW; Azzam G; Mohana-Kumaran N
Discov Oncol; 2022 Feb; 13(1):9. PubMed ID: 35201512
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression.
Sumarni U; Zhu J; Sinnberg T; Eberle J
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293331
[TBL] [Abstract][Full Text] [Related]
6. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
7. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer.
Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN
Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
Lian BSX; Yek AEH; Shuvas H; Abdul Rahman SF; Muniandy K; Mohana-Kumaran N
BMC Res Notes; 2018 Mar; 11(1):197. PubMed ID: 29580266
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
[TBL] [Abstract][Full Text] [Related]
10. Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors.
Senichkin VV; Pervushin NV; Zamaraev AV; Sazonova EV; Zuev AP; Streletskaia AY; Prikazchikova TA; Zatsepin TS; Kovaleva OV; Tchevkina EM; Zhivotovsky B; Kopeina GS
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008345
[TBL] [Abstract][Full Text] [Related]
11. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
Wang Q; Wan J; Zhang W; Hao S
Leuk Lymphoma; 2019 Sep; 60(9):2170-2180. PubMed ID: 30626241
[TBL] [Abstract][Full Text] [Related]
12. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
13. Co-operation of MCL-1 and BCL-X
Galas-Filipowicz D; Chavda SJ; Gong JN; Huang DCS; Khwaja A; Yong K
Front Oncol; 2024; 14():1394393. PubMed ID: 38651147
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers.
Williams MM; Elion DL; Rahman B; Hicks DJ; Sanchez V; Cook RS
Oncotarget; 2019 Sep; 10(52):5389-5402. PubMed ID: 31595181
[TBL] [Abstract][Full Text] [Related]
15. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
16. A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML.
Wang Q; Hao S
Oncol Lett; 2019 Nov; 18(5):5481-5489. PubMed ID: 31612056
[TBL] [Abstract][Full Text] [Related]
17. Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.
Erdogdu U; Dolgikh N; Laszig S; Särchen V; Meister MT; Wanior M; Knapp S; Boedicker C
Neoplasia; 2022 Feb; 24(2):109-119. PubMed ID: 34959030
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
19. Bcl-x
Hoffmeister-Wittmann P; Mock A; Nichetti F; Korell F; Heilig CE; Scherr AL; Günther M; Albrecht T; Kelmendi E; Xu K; Nader L; Kessler A; Schmitt N; Fritzsche S; Weiler S; Sobol B; Stenzinger A; Boeck S; Westphalen CB; Schulze-Osthoff K; Trojan J; Kindler T; Weichert W; Spiekermann K; Bitzer M; Folprecht G; Illert AL; Boerries M; Klauschen F; Ochsenreither S; Siveke J; Bauer S; Glimm H; Brors B; Hüllein J; Hübschmann D; Uhrig S; Horak P; Kreutzfeldt S; Banales JM; Springfeld C; Jäger D; Schirmacher P; Roessler S; Ormanns S; Goeppert B; Fröhling S; Köhler BC
Liver Int; 2022 Dec; 42(12):2855-2870. PubMed ID: 35983950
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
